Caspase-11 deficiency in vivo and caspase-4 silencing in the human pulmonary arterial endothelial cells in vitro alleviated the development of PAH [49], and inhibition of Caspase-1 also attenuated the pathogenesis of PAH [50]. Here, CASP4 is linked to pulmonary arterial hypertension.